Citi analyst Joanne Wuensch lowered the firm’s price target on Sight Sciences (SGHT) to $4.35 from $5 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The “walls of worry are high” into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm’s top picks are now Edwards Lifesciences and Intuitive Surgical.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Wins Key Patent Ruling in Glaucoma Case
- Sight Sciences awarded monetary damages by district court against Alcon
- Sight Sciences price target lowered to $5 from $6.50 at Citi
- Sight Sciences Earnings Call Highlights Disciplined Growth
- Sight Sciences price target lowered to $6.50 from $9.10 at Citi